Tengrinews TV Радио Tengri FM Радио Жұлдыз FM Laws of Kazakhstan
KZ RU EN
Write us +7 (727) 388 8020 +7 (717) 254 2710
искать через Tengrinews.kz
искать через Google
искать через Yandex
USD / KZT - 316.56
EUR / KZT - 342.14
CNY / KZT - 45.99
RUB / KZT - 5.52

New drug said to reduce heart damage during surgery

11 march 2013, 12:15
0
©REUTERS
©REUTERS
A single dose of an experimental anti-inflammatory treatment reduces heart muscle damage during an angioplasty operation to open blocked arteries, AFP reports citing a study.

The antibody inclacumab, developed by Swiss lab Hoffmann-La Roche, significantly reduced levels of the standard molecular markers troponin I and CK-MB in patients, compared to those who took a placebo in a clinical trial.

Patients who received the inclacumab dose saw troponin I levels drop 22.4 percent more after 16 hours and 24.4 percent after more at 24 hours (p=0.05), compared with patients on a placebo.

CK-MB levels dropped 16.3 percent more after 16 hours and 17.4 percent more at 24 hours, compared with patients on placebo.

"It was exciting to see that a single administration of inclacumab would yield clinical benefit," said the study's lead investigator Jean-Claude Tardif, director of the Research Center at the Montreal Heart Institute.

The phase II trial examined 530 patients with a median age of 61 experiencing a type of heart attack called non-ST-elevation myocardial infarction or NSTEMI.

Patients were randomized to receive an infusion of inclacumab of 20 milligrams per kilogram, five milligrams per kilogram or a placebo one hour before angioplasty.

The researchers also found that 24 hours after angioplasty, 18.3 percent of patients on the placebo had CK-MB increases more than three times the upper limit of normal.

Many clinical trials define that threshold as the onset of a post-angioplasty heart attack.

But only 8.9 percent of patients who received the higher dose of inclacumab experienced those same CK-MB increases.

"If we're able to confirm these results in potential future studies, this drug could become part of the therapeutic armamentarium in modern cardiology," Tardif said in a statement.

"You could use this drug more widely, in all patients coming in with heart attacks, although that would require additional large studies."

More than a million coronary angioplasty procedures are performed in the United States each year, costing more than $10 billion.

Angioplasty can damage heart tissue, which can trigger a need for more procedures, poor outcomes and higher health care costs .

During angioplasty, surgeons insert a balloon catheter to mechanically widen narrowed or obstructed arteries.

Нравится
Add comment
Most Read
Most Discussed
Today
Week
Month